Fig. 3.

Clinical efficacy of anlotinib maintenance treatment. (A) The best percentage change in target lesions by RECIST version 1.1 (n = 48). Bars with different colours represent patients with different subtypes. Patients were defined as partial response (PR) with bars of over 30% reduction, progressive disease (PD) with bars of over 20% increase, and as stable disease (SD) with bars between 30% reduction and 20% increase (cut-offs represented by the dashed lines). Asterisks refer to patients with new lesions who were also assessed as PD. (B) Tumour regression of the patient with gastric synovial sarcoma. Computed tomography (CT) scans showed that the patient, who had primary synovial sarcoma in the stomach and metastasis in the liver, achieved SD after 6 cycles of first-line anthracycline-based chemotherapy and reached complete response (CR) after receiving 23 cycles of anlotinib maintenance treatment. Red arrows indicate the lesions. (C) Swimmer plot represents the duration of responses. The length of each bar represents each patient's treatment duration. The red triangles, blue triangles and green circles indicate the point in time when the best CR, PR and SD responses are first achieved. The purple triangles indicate the progression time. Other subtypes included angiosarcoma (n = 1), undifferentiated pleomorphic sarcoma (n = 1), low-grade myofibroblastic sarcoma (n = 1), sclerosing epithelioid fibrosarcoma (n = 1), epithelioid sarcoma (n = 1), epithelioid haemangioendothelioma (n = 1) and extraskeletal myxoid chondrosarcoma (n = 1). SD = stable disease. CR = complete response.